Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. is set to present promising pre-clinical data on its innovative IL-2 Superkines, MDNA11, at two major oncology conferences. These presentations could attract investor interest as they highlight advancements in treating aggressive cancers like glioblastoma and breast cancer.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
